Anacor Pharmaceuticals Inc  

(Public, NASDAQ:ANAC)   Watch this stock  
Find more results for ANAC
+7.65 (6.35%)
Oct 2 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 115.40 - 128.68
52 week 22.29 - 156.93
Open 117.89
Vol / Avg. 0.00/751,653.00
Mkt cap 5.64B
P/E     -
Div/yield     -
EPS -1.58
Shares 44.02M
Beta 1.65
Inst. own 91%
Nov 4, 2015
Q3 2015 Anacor Pharmaceuticals Inc Earnings Release (Estimated) - 4:00PM EST - Add to calendar
Sep 16, 2015
Anacor Pharmaceuticals Inc at Morgan Stanley Healthcare Conference
Aug 11, 2015
Anacor Pharmaceuticals Inc at Wedbush PacGrow Healthcare Conference
Aug 6, 2015
Q2 2015 Anacor Pharmaceuticals Inc Earnings Call - Webcast
Aug 6, 2015
Q2 2015 Anacor Pharmaceuticals Inc Earnings Release
Jul 13, 2015
Anacor Pharmaceuticals Inc Crisaborole Phase 3 Pivotal Studies With Mild-to-Moderate Atopic Dermatitis Top-Line Results Conference Call - Webcast
More events from DailyFinance »    

Key stats and ratios

Q2 (Jun '15) 2014
Net profit margin -61.85% -421.28%
Operating margin -56.22% -449.66%
EBITD margin - -436.51%
Return on average assets -25.78% -45.72%
Return on average equity -76.78% -87.03%
Employees 100 -
CDP Score - -


1020 East Meadow Circle
PALO ALTO, CA 94303-4230
United States - Map
+1-650-5437500 (Phone)
+1-650-5437660 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money


Anacor Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on discovering, developing and commercializing small-molecule therapeutics derived from its boron chemistry platform. The Company's lead product candidate, AN2728 is an investigational non-steroidal topical PDE-4 inhibitor in development for the potential treatment of mild-to-moderate atopic dermatitis and psoriasis. The Company's product KERYDIN (tavaborole) topical solution is an oxaborole antifungal. The Company also has a pipeline of other internally discovered topical and systemic boron-based compounds in early stages of research and development, which include AN3365. The Company's compound, AN5568 (SCYX-7158), is licensed to Drugs for Neglected Diseases initiative (DNDi) for the potential treatment of human African trypanosomiasis (sleeping sickness).

Officers and directors

Paul L. Berns Chairman of the Board, President, Chief Executive Officer
Age: 48
Bio & Compensation  - Reuters
Graeme Bell Chief Financial Officer, Executive Vice President
Bio & Compensation  - Reuters
Vincent P. Ippolito Executive Vice President, Chief Commercial Officer
Age: 56
Bio & Compensation  - Reuters
Ryan T. Sullivan Senior Vice President, General Counsel, Secretary
Age: 39
Bio & Compensation  - Reuters
Sanjay Chanda Ph.D. Senior Vice President - Drug Development
Age: 50
Bio & Compensation  - Reuters
Kirk R. Maples Ph.D. Senior Vice President - Program Management
Age: 56
Bio & Compensation  - Reuters
Jacob J. Plattner Ph.D. Senior Vice President - Research
Age: 68
Bio & Compensation  - Reuters
Carmen R. Rodriguez Ph.D. Senior Vice President - Regulatory Affairs and Quality Assurance
Age: 66
Bio & Compensation  - Reuters
Lee T. Zane M.D. Senior Vice President - Clinical Development, Chief Medical Officer
Age: 45
Bio & Compensation  - Reuters
William J. Rieflin Lead Independent Director
Age: 55
Bio & Compensation  - Reuters